Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.75 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | LSS | P48449 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10800722 | 0.91 | LSS (0.70) | LTA4HMCHR1EGFRHRH3LSS | |
| SCHEMBL29985909 | 0.90 | LTA4H (0.62) | LTA4HMCHR1EGFRLSSCHRNB2 | |
| SCHEMBL7370378 | 0.88 | LSS (0.61) | LTA4HMCHR1EGFRHRH3LSS | |
| SCHEMBL1959363 | 0.88 | CHRNB2 (0.64) | LTA4HMCHR1LMNACHRNB2CHRNA4 | |
| SCHEMBL9097342 | 0.88 | EGFR (0.69) | LTA4HMCHR1EGFRESR1GAA | |
| Hydrochloric Acid SCHEMBL7371413 | 0.87 | LSS (0.59) | LTA4HMCHR1EGFRHRH3LSS | |
| SCHEMBL9099717 | 0.86 | LTA4H (0.57) | LTA4HMCHR1EGFRESR1RAB9A | |
| SCHEMBL11253539 | 0.86 | LTA4H (0.81) | LTA4HHRH3KEAP1NFE2L2LSS | |
| SCHEMBL13588339 | 0.86 | LTA4H (1.00) | LTA4HHRH3KEAP1NFE2L2LSS | |
| SCHEMBL1405661 | 0.85 | LTA4H (0.85) | LTA4HEGFRHRH3KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2373163-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1641745-B1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | ORION CORP (FI) | 2010-04-14 | — | — | EP | disclosed |
| US-7390923-B2 | Propionamide derivatives useful as androgen receptor modulators | ORION CORPORATION (FI) | 2008-06-24 | — | — | US | disclosed |
| US-20070123512-A1 | Propionamide derivatives useful as androgen receptor modulators | ORION CORPORATION (FI) | 2007-05-31 | — | — | US | disclosed |
| EP-1641745-A1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | Orion Corporation (FI) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000794-A1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | ORION CORPORATION (FI) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123512-A1 | Propionamide derivatives useful as androgen receptor modulators | NR5A1, FSHR, GNRHR | LTA4H 1034/4885MCHR1 674/4885EGFR 2465/4885 |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | LTA4H 2825/4885MCHR1 3512/4885EGFR 2847/4885 |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | CASR, CALCR, ORAI1 | LTA4H 3218/4885MCHR1 885/4885EGFR 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.